To directly compare the efficacy of natalizumab and fingolimod in patients with active relapsing-remitting multiple sclerosis.
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study / Butzkueven, Helmut; Licata, Stephanie; Jeffery, Douglas; Arnold, Douglas L; Filippi, Massimo; Geurts, Jeroen Jg; Santra, Sourav; Campbell, Nolan; Ho, Pei-Ran. - In: BMJ OPEN. - ISSN 2044-6055. - 10:10(2020). [10.1136/bmjopen-2020-038861]
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Filippi, Massimo;
2020-01-01
Abstract
To directly compare the efficacy of natalizumab and fingolimod in patients with active relapsing-remitting multiple sclerosis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
